Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 13/20 | 1.00 |
| ▸ | FGFR3 | P22607 | 8/20 | 1.00 |
| ▸ | FGFR4 | P22455 | 6/20 | 1.00 |
| ▸ | FGFR2 | P21802 | 4/20 | 1.00 |
| ▸ | EGFR | P00533 | 1/20 | 1.00 |
| ▸ | JAK2 | O60674 | 2/20 | 0.63 |
| ▸ | ABL1 | P00519 | 2/20 | 0.63 |
| ▸ | INSR | P06213 | 2/20 | 0.63 |
| ▸ | LCK | P06239 | 2/20 | 0.63 |
| ▸ | FYN | P06241 | 2/20 | 0.63 |
| ▸ | YES1 | P07947 | 2/20 | 0.63 |
| ▸ | LYN | P07948 | 2/20 | 0.63 |
| ▸ | RET | P07949 | 2/20 | 0.63 |
| ▸ | MET | P08581 | 2/20 | 0.63 |
| ▸ | ROS1 | P08922 | 2/20 | 0.63 |
| ▸ | KIT | P10721 | 2/20 | 0.63 |
| ▸ | SRC | P12931 | 2/20 | 0.63 |
| ▸ | BRAF | P15056 | 2/20 | 0.63 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.63 |
| ▸ | FLT1 | P17948 | 2/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17857056 | 1.00 | FGFR1 (1.00) | FGFR1FGFR3FGFR4FGFR2EGFR | |
| SCHEMBL19441967 | 0.92 | FGFR3 (0.84) | FGFR1FGFR3FGFR4FGFR2EGFR | |
| SCHEMBL19753756 | 0.90 | FGFR3 (0.82) | FGFR1FGFR3FGFR4FGFR2EGFR | |
| SCHEMBL374413 | 0.86 | FGFR3 (0.81) | FGFR1FGFR3FGFR4FGFR2EGFR | |
| SCHEMBL583166 | 0.82 | FGFR3 (0.86) | FGFR1FGFR3FGFR4FGFR2EGFR | |
| SCHEMBL20867981 | 0.82 | FGFR1 (0.69) | FGFR1FGFR3FGFR4FGFR2EGFR | |
| SCHEMBL20867713 | 0.82 | FGFR1 (0.69) | FGFR1FGFR3FGFR4FGFR2EGFR | |
| SCHEMBL374643 | 0.82 | FGFR3 (0.72) | FGFR1FGFR3FGFR4FGFR2EGFR | |
| SCHEMBL19507407 | 0.81 | FGFR4 (0.75) | FGFR1FGFR3FGFR4FGFR2EGFR | |
| SCHEMBL2017841 | 0.81 | FGFR3 (0.84) | FGFR1FGFR3FGFR4FGFR2EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250353912-A1 | COMPOSITIONS AND METHODS COMPRISING ANTIBODIES THAT BIND TO COVALENT PEPTIDE CONJUGATES | UNIV NEW YORK (US) | 2025-11-20 | — | — | US | claimed |
| US-20250235456-A1 | METHODS OF USE FOR AZA-QUINAZOLINE COMPOUNDS | IAMBIC THERAPEUTICS, INC. | 2025-07-24 | — | — | US | claimed |
| EP-4543931-A2 | COMPOSITIONS AND METHODS COMPRISING ANTIBODIES THAT BIND TO COVALENT PEPTIDE CONJUGATES | New York University (US) | 2025-04-30 | — | — | EP | claimed |
| CN-119866347-A | Compositions and methods comprising antibodies conjugated to covalent peptide conjugates | 纽约大学 | 2025-04-22 | — | — | CN | claimed |
| WO-2023250391-A9 | COMPOSITIONS AND METHODS COMPRISING ANTIBODIES THAT BIND TO COVALENT PEPTIDE CONJUGATES | NEW YORK UNIVERSITY (US) | 2024-04-25 | — | — | WO | claimed |
| WO-2023250391-A2 | COMPOSITIONS AND METHODS COMPRISING ANTIBODIES THAT BIND TO COVALENT PEPTIDE CONJUGATES | NEW YORK UNIVERSITY (US) | 2023-12-28 | — | — | WO | claimed |
| US-20220412957-A1 | METHODS OF TREATING CANCER PATIENTS WITH RAS NODE OR RTK TARGETED THERAPEUTIC AGENTS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2022-12-29 | — | — | US | claimed |
| EP-4073516-A1 | METHODS OF TREATING CANCER PATIENTS WITH RAS NODE OR RTK TARGETED THERAPEUTIC AGENTS | Celcuity Inc. (US) | 2022-10-19 | — | — | EP | claimed |
| EP-4731674-A2 | COMPOSITIONS AND METHODS FOR BINDING TO COVALENT PEPTIDE CONJUGATES | New York University (US) | 2026-04-29 | — | — | EP | disclosed |
| EP-3954436-B1 | METHOD FOR PRODUCING BIOTISSUE-LIKE STRUCTURE | ORIZURU THERAPEUTICS INC (JP) | 2026-01-07 | — | — | EP | disclosed |
| WO-2025226775-A2 | COMPOSITIONS AND METHODS FOR BINDING TO COVALENT PEPTIDE CONJUGATES | NEW YORK UNIVERSITY (US) | 2025-10-30 | — | — | WO | disclosed |
| US-20250304585-A1 | SULFAMATE BASED COVALENT LIGAND-DIRECTED RELEASE (COLDR) COMPOUNDS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2025-10-02 | — | — | US | disclosed |
| EP-4615869-A1 | COMBINATION THERAPY COMPRISING BISPECIFIC ANTIBODIES COMPRISING AN NRP1 BINDING DOMAIN | Pinetree Therapeutics, Inc. (US) | 2025-09-17 | — | — | EP | disclosed |
| US-12391770-B2 | Compositions and methods comprising antibodies that bind to covalent peptide conjugates | NEW YORK UNIVERSITY (US) | 2025-08-19 | — | — | US | disclosed |
| WO-2022172960-A1 | MATURATION AGENT | オリヅルセラピューティクス株式会社 | 2022-08-18 | — | — | WO | disclosed |
| US-20220168357-A1 | METHOD FOR PRODUCING BIOLOGICAL TISSUE-LIKE STRUCTURE | Orizuru Therapeutics, Inc. (JP) | 2022-06-02 | — | — | US | disclosed |
| CN-114224892-A | TIPE2 inhibitor, application thereof, screening method and screening device | 中国科学院深圳理工大学(筹) | 2022-03-25 | — | — | CN | disclosed |
| US-20220081438-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS INHIBITORS OF FGFR TYROSINE KINASES | ARRAY BIOPHARMA INC. | 2022-03-17 | — | — | US | disclosed |
| EP-3954436-A1 | METHOD FOR PRODUCING BIOTISSUE-LIKE STRUCTURE | Orizuru Therapeutics, Inc. (JP) | 2022-02-16 | — | — | EP | disclosed |
| CN-113993528-A | Method for producing living body-like tissue structure | 千纸鹤治疗公司 | 2022-01-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250235456-A1 | METHODS OF USE FOR AZA-QUINAZOLINE COMPOUNDS | AZI2, TPMT, HDAC10 | FGFR1 3506/4885FGFR3 4067/4885FGFR4 4248/4885 |
| US-20250353912-A1 | COMPOSITIONS AND METHODS COMPRISING ANTIBODIES THAT BIND TO COVALENT PEPTIDE CONJUGATES | MICA, CD74, HLA-DRB1 | FGFR1 3437/4885FGFR3 2478/4885FGFR4 3469/4885 |
| US-20250304585-A1 | SULFAMATE BASED COVALENT LIGAND-DIRECTED RELEASE (COLDR) COMPOUNDS | CASR, NPSR1, GSR | FGFR1 233/4885FGFR3 181/4885FGFR4 387/4885 |
| US-20220081438-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS INHIBITORS OF FGFR TYROSINE KINASES | FGFR1, FGFR4, FGFR3 | FGFR1 1/4885FGFR3 3/4885FGFR4 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.